◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Beijing Tong Ren Tang Chinese Medicine Company Limited (3613) Financial History

Name: Beijing Tong Ren Tang Chinese Medicine Company Limited (3613) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-10

Beijing Tong Ren Tang Chinese Medicine Company Limited (3613) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Wan Chai, Hong Kong with about 780 employees. Its market capitalization is roughly HKD 6 billion. In the fiscal year ended 2025-12-31, 3613 reported HKD 1.5B in revenue and HKD 397M in net income.

Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine products to wholesalers and individuals. It operates through Hong Kong, Mainland China, and Overseas segments.

Interactive charts & full statements →

3613 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	HKD 1.5B	HKD 1.6B	HKD 1.5B	HKD 1.7B
Gross Profit	HKD 926M	HKD 1.1B	HKD 1.0B	HKD 1.2B
Operating Income (EBIT)	HKD 536M	HKD 574M	HKD 639M	HKD 815M
Net Income	HKD 397M	HKD 500M	HKD 540M	HKD 646M

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

3613 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(HKD 293M)	(HKD 276M)	(HKD 276M)	(HKD 444M)	—

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

3613 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	HKD 4.7B	HKD 4.6B	HKD 4.4B	HKD 4.2B	—
Total Liabilities	HKD 292M	HKD 313M	HKD 414M	HKD 486M	—

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 3613 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

2005 · SSY Group Limited — $7 billion
2575 · Xuanzhu Biopharmaceutical Co., Ltd. — $6 billion
6185 · CanSino Biologics Inc. — $6 billion
4539 · Nippon Chemiphar Co., Ltd. — $6 billion
INDV · Indivior Pharmaceuticals, Inc. — $5 billion
0719 · Shandong Xinhua Pharmaceutical Company Limited — $4 billion
CURA · Curaleaf Holdings, Inc. — $3 billion
SFZN · Siegfried Holding AG — $3 billion

← 3612 All “0-9” companies 3616 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.